Drug name - Opana Er
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7851482 | ENDO PHARMS | Method for making analgesics |
Jul, 2029
(6 years from now) | |
| US8871779 | ENDO PHARMS | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
Nov, 2029
(7 years from now) | |
| CN101395159A | ENDO PHARMS | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds |
Dec, 2011
(10 years ago) | |
| CN101652371A | ENDO PHARMS | Improved Method For Producing Analgesics |
Jun, 2012
(10 years ago) | |
| CN102391271A | ENDO PHARMS | Improved Method For Making Analgesics |
Dec, 2019
(2 years ago) | |
| CN102391271B | ENDO PHARMS | Improved Method For Producing Analgesics |
Dec, 2019
(2 years ago) | |
| EP1994034A2 | ENDO PHARMS | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds |
Mar, 2027
(4 years from now) | |
| EP1994034B1 | ENDO PHARMS | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds |
Mar, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8329216 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(4 months from now) | |
| US8309112 | ENDO PHARMS | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
Feb, 2023
(4 months from now) | |
| US8309122 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(4 months from now) | |
| US7276250 | ENDO PHARMS | Sustained release formulations of oxymorphone |
Feb, 2023
(4 months from now) | |
| US8075872 | ENDO PHARMS | Abuse-proofed dosage form |
Nov, 2023
(1 year, 1 month from now) | |
| US8309060 | ENDO PHARMS | Abuse-proofed dosage form |
Nov, 2023
(1 year, 1 month from now) | |
| US8114383 | ENDO PHARMS | Abuse-proofed dosage form |
Aug, 2024
(1 year, 10 months from now) | |
| US8192722 | ENDO PHARMS | Abuse-proof dosage form |
Sep, 2025
(2 years from now) | |
| US8808737 | ENDO PHARMS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(4 years from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Treatment: Relief of moderate to severe pain; Dose modification for renal impairment
Dosage: TABLET, EXTENDED RELEASE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 5MG | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
| 7.5MG | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
| 10MG | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
| 15MG | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
| 20MG | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
| 30MG | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
| 40MG | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.